FDA postpones decision for Pfizer's weekly growth hormone treatment
Ascendis continues as the sole once-weekly growth hormone treatment for children with growth hormone deficiency after the US Food and Drug Administration has extended its review period of Pfizer and Opko's competitor drug.
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY DANIEL PEDERSEN
Pfizer and partner Opko Health must wait patiently before knowing the final fate of its drug candidate somatrogon on the US market, as the US Food and Drug Administration (FDA) has extended the deadline for its review by three months, pushing the final decision into January of next year, Pfizer writes in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Ascendis ready with clinical trial of another cancer drug
For subscribers
Pfizer may present new growth hormone in 2022
For subscribers
.jpg&w=384&q=75)
